Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of MDS. We evaluated the clinicop...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Takahashi, Koichi, Jabbour, Elias, Borthakur, Gautham, Pemmaraju, Naveen, Konopleva, Marina, Soltysiak, Kelly A., Pierce, Sherry R., Bueso-Ramos, Carlos E., Patel, Keyur P., Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013259/
https://ncbi.nlm.nih.gov/pubmed/32027746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001101
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares